BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 33871726)

  • 1. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
    Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
    Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-based contrast agents: A comprehensive risk assessment.
    Fraum TJ; Ludwig DR; Bashir MR; Fowler KJ
    J Magn Reson Imaging; 2017 Aug; 46(2):338-353. PubMed ID: 28083913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
    Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
    Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
    Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS
    Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of gadolinium-based contrast agents (GBCAs)-adverse reactions.
    Boehm IB
    Magn Reson Imaging; 2022 Jan; 85():1-2. PubMed ID: 34662698
    [No Abstract]   [Full Text] [Related]  

  • 9. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
    Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
    Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
    Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
    Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
    Penfield JG
    Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
    Holowka S; Shroff M; Chavhan GB
    Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
    Bäuerle T; Saake M; Uder M
    Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
    McDonald JS; McDonald RJ
    Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
    Piersson AD; Gorleku PN
    Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 18. Gadolinium contrast agents - are they really safe?
    Malikova H; Holesta M
    J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
    Sardanelli F; Cozzi A; Trimboli RM; Schiaffino S
    AJR Am J Roentgenol; 2020 Feb; 214(2):324-327. PubMed ID: 31799869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.